AP783A - Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. - Google Patents

Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. Download PDF

Info

Publication number
AP783A
AP783A APAP/P/1997/000939A AP9700939A AP783A AP 783 A AP783 A AP 783A AP 9700939 A AP9700939 A AP 9700939A AP 783 A AP783 A AP 783A
Authority
AP
ARIPO
Prior art keywords
composition
tumor
cancer
pharmaceutically acceptable
compound
Prior art date
Application number
APAP/P/1997/000939A
Other languages
English (en)
Other versions
AP9700939A0 (en
Inventor
Chung K Chu
Young-Chi Cheng
Original Assignee
Univ Georgia
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/301,298 external-priority patent/US5817667A/en
Application filed by Univ Georgia, Univ Yale filed Critical Univ Georgia
Publication of AP9700939A0 publication Critical patent/AP9700939A0/xx
Application granted granted Critical
Publication of AP783A publication Critical patent/AP783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
APAP/P/1997/000939A 1994-09-06 1995-09-05 Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents. AP783A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/301,298 US5817667A (en) 1991-04-17 1994-09-06 Compounds and methods for the treatment of cancer
US39063395A 1995-02-17 1995-02-17
PCT/US1995/011464 WO1996007413A1 (en) 1994-09-06 1995-09-05 Compounds and methods for the treatment of cancer

Publications (2)

Publication Number Publication Date
AP9700939A0 AP9700939A0 (en) 1997-04-30
AP783A true AP783A (en) 1999-11-17

Family

ID=26972285

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/000939A AP783A (en) 1994-09-06 1995-09-05 Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents.

Country Status (31)

Country Link
US (3) US6063787A (ja)
EP (2) EP0781136B1 (ja)
JP (1) JP3979662B2 (ja)
KR (1) KR100374477B1 (ja)
CN (3) CN1827108A (ja)
AP (1) AP783A (ja)
AT (1) ATE267015T1 (ja)
AU (1) AU704977B2 (ja)
BG (1) BG63122B1 (ja)
BR (1) BR9508886A (ja)
CA (1) CA2199117C (ja)
CZ (1) CZ297873B6 (ja)
DE (1) DE69533066T2 (ja)
DK (1) DK0781136T3 (ja)
ES (1) ES2219666T3 (ja)
FI (1) FI970918A (ja)
HU (1) HUT77172A (ja)
IL (1) IL115156A (ja)
IS (1) IS2011B (ja)
MY (1) MY121548A (ja)
NO (1) NO313268B1 (ja)
NZ (1) NZ335013A (ja)
OA (1) OA10473A (ja)
PL (2) PL188359B1 (ja)
PT (1) PT781136E (ja)
RO (1) RO118748B1 (ja)
RU (1) RU2168995C2 (ja)
SI (1) SI0781136T1 (ja)
SK (1) SK284564B6 (ja)
WO (1) WO1996007413A1 (ja)
ZA (1) ZA957483B (ja)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
CN1307421C (zh) 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
DE69900841T2 (de) 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
BR9908270A (pt) 1998-02-25 2004-06-29 Univ Emory 2-fluoro-nucleosìdeos, composições farmacêuticas e seus usos
CA2366012A1 (en) * 1999-03-29 2000-10-05 Shire Biochem Inc. Methods of treating leukemia
AU2004201676B2 (en) * 1999-03-29 2006-03-09 University Of Georgia Research Foundation, Inc. Methods of treating leukemia
US6653318B1 (en) 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US6583149B1 (en) 1999-09-24 2003-06-24 Biochem Pharma Inc. Method for the treatment or prevention of viral infection using nucleoside analogues
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EP1600452A3 (en) 1999-11-12 2008-09-10 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
PL361310A1 (en) * 2000-10-13 2004-10-04 Shire Biochem Inc. Dioxolane analogs for improved inter-cellular delivery
CA2441350A1 (en) 2001-01-19 2002-07-25 Newbiotics, Inc. Methods to treat autoimmune and inflammatory conditions
CN1744902B (zh) * 2001-03-23 2010-05-26 希拉加拿大股份有限公司 治疗癌症的药物组合
DE60234577D1 (de) 2001-03-23 2010-01-14 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs, die dioxolan nukleosidanalogen enthält
US20030027799A1 (en) * 2001-03-30 2003-02-06 Shire Biochem Inc. Methods of treating cancer using a combination of drugs
AU2002336864B2 (en) * 2001-11-02 2006-08-17 Shire Biochem Inc. Pharmaceutical compositions for the treatment of leukemia comprising dioxolane nucleosides analogs
PT1448186E (pt) * 2001-11-19 2009-03-24 Medigene Ag Medicamento para o tratamento de doenças virais da pele e doenças tumorais
JP4299779B2 (ja) 2002-06-21 2009-07-22 エルジー エレクトロニクス インコーポレーテッド ビデオデータの再生を管理するためのデータ構造を有する記録媒体
MXPA04002365A (es) 2002-06-21 2004-11-22 Lg Electronics Inc Medio de grabacion que tiene estructura de datos para manejar la reproduccion de datos de video grabados en el mismo.
KR20040000290A (ko) 2002-06-24 2004-01-03 엘지전자 주식회사 고밀도 광디스크의 멀티 경로 데이터 스트림 관리방법
WO2004001751A1 (en) 2002-06-24 2003-12-31 Lg Electronics Inc. Recording medium having data structure including navigation control information for managing reproduction of video data recorded thereon and recording and reproducing methods and apparatuses
CA2459086C (en) 2002-06-28 2013-08-13 Lg Electronics Inc. Recording medium having data structure for managing recording and reproduction of multiple path data recorded thereon and recording and reproducing methods and apparatus
RU2347284C2 (ru) 2002-10-14 2009-02-20 Эл Джи Электроникс Инк. Носитель записи со структурой данных для управления воспроизведением записанного на нем множества аудиопотоков и способы и устройства записи и воспроизведения
CN100479051C (zh) 2002-10-15 2009-04-15 Lg电子有限公司 具有管理多路图形流重现的数据结构的记录介质及记录和重现方法和装置
US7720356B2 (en) 2002-11-12 2010-05-18 Lg Electronics Inc Recording medium having data structure for managing reproduction of multiple reproduction path video data recorded thereon and recording and reproducing methods and apparatuses
US7664372B2 (en) 2002-11-20 2010-02-16 Lg Electronics Inc. Recording medium having data structure for managing reproduction of multiple component data recorded thereon and recording and reproducing methods and apparatuses
US7693394B2 (en) 2003-02-26 2010-04-06 Lg Electronics Inc. Recording medium having data structure for managing reproduction of data streams recorded thereon and recording and reproducing methods and apparatuses
US7809775B2 (en) 2003-02-27 2010-10-05 Lg Electronics, Inc. Recording medium having data structure for managing playback control recorded thereon and recording and reproducing methods and apparatuses
EP1604356A4 (en) 2003-02-28 2009-12-16 Lg Electronics Inc RECORD MEDIUM WITH A DATA STRUCTURE FOR MANAGING THE RANDOM / SHUFFLE PLAYBACK OF RECORDED VIDEO DATA, AND METHOD AND DEVICES FOR RECORDING AND PLAYING
US7620301B2 (en) 2003-04-04 2009-11-17 Lg Electronics Inc. System and method for resuming playback
AU2004281525B2 (en) 2003-10-09 2010-01-28 Aresus Pharma GmbH The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CN103735560A (zh) 2005-06-07 2014-04-23 耶鲁大学 使用克来夫定和替比夫定治疗癌症和其它病症或疾病状态的方法
US7951788B2 (en) * 2005-12-02 2011-05-31 Yale University Method of treating cancer and other conditions or disease states using L-cytosine nucleoside analogs
NO324263B1 (no) 2005-12-08 2007-09-17 Clavis Pharma Asa Kjemiske forbindelser, anvendelse derav ved behandling av kreft, samt farmasoytiske preparater som omfatter slike forbindelser
CN101534835B (zh) * 2006-09-01 2012-05-30 佐治亚大学研究基金会 用于癌症的L-OddC的前药
CN102406649A (zh) * 2011-11-15 2012-04-11 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
CN103720693A (zh) * 2011-11-15 2014-04-16 张始状 人体五种正常碱基在制备治疗肿瘤药物中的应用
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
CN110168092A (zh) * 2016-12-28 2019-08-23 特朗斯吉有限公司 溶瘤病毒和治疗分子
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
EP0337713A2 (en) * 1988-04-11 1989-10-18 Biochem Pharma Inc 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
EP0206497B1 (en) * 1985-05-15 1994-07-20 The Wellcome Foundation Limited Therapeutic nucleosides and their preparation
JPS62501712A (ja) * 1985-08-26 1987-07-09 アメリカ合衆国 ２′、３′―ジデオキシイノシン、２′，３′―ジデオキシグアノシンまたは２′，３′―ジデオキシアデノシンを含有する抗ｈｔｌｖ―３／ｌａｖ剤
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
DK167377B1 (da) * 1985-09-17 1993-10-25 Wellcome Found 3'-azidopyrimidinnucleosider eller farmaceutisk acceptable salte eller estere deraf til anvendelse ved behandling af eller profylakse for en human retrovirusinfektion
IN164556B (ja) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
FR2601385B1 (fr) * 1986-07-09 1989-09-29 Sucre Rech & Dev Procede de preparation a partir de saccharose d'un melange de sucres a haute teneur en isomaltose par voie enzymatique et produits obtenus
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
US5215971A (en) * 1986-12-19 1993-06-01 Medivir Ab Antiviral pharmaceutical composition comprising 5-substituted pyrimidine nucleosides
NZ223990A (en) * 1987-03-24 1990-08-28 Nycomed As Acylated 2',3'-dideoxynucleosides and pharmaceutical compositions
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
SE8802687D0 (sv) * 1988-07-20 1988-07-20 Astra Ab Nucleoside derivatives
EP0375329B1 (en) * 1988-12-19 1995-05-31 The Wellcome Foundation Limited Antiviral pyrimidine and purine compounds, process for their preparation and pharmaceutical compositions containing them
UA45942A (uk) * 1989-02-08 2002-05-15 Біокем Фарма, Інк. 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5527782A (en) * 1990-03-13 1996-06-18 Acic (Canada) Inc. 5-halo-2,3'-O-cyclocytidines
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
AU9125991A (en) * 1990-12-05 1992-07-08 University Of Georgia Research Foundation, Inc., The Enantiomerically pure beta -l-(-)-1,3-oxathiolane nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int PHARMACEUTICAL PREPARATIONS CONTAINING CIS-4-AMINO-1-) 2-HYDROXIMETHIL-1,3-OXETYOLEN-5-IL (-
NZ250842A (en) * 1991-02-22 1996-03-26 Univ Emory Resolution of a racemic mixture of nucleoside enantiomers such as 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane (ftc)
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
SK279542B6 (sk) * 1991-03-06 1998-12-02 The Wellcome Foundation Limited U
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9226927D0 (en) 1992-12-24 1993-02-17 Iaf Biochem Int Dideoxy nucleoside analogues
US5627160A (en) * 1993-05-25 1997-05-06 Yale University L-2',3'-dideoxy nucleoside analogs as anti-hepatitis B (HBV) and anti-HIV agents
WO1995018137A1 (en) * 1993-12-30 1995-07-06 Genta Incorporated Improved process for the purification of oligomers
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5971983A (en) * 1997-05-09 1999-10-26 The Regents Of The University Of California Tissue ablation device and method of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
EP0337713A2 (en) * 1988-04-11 1989-10-18 Biochem Pharma Inc 2-Substituted-4-Substituted-1,3-Dioxolanes, Synthesis and use thereof
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections

Also Published As

Publication number Publication date
IL115156A (en) 2000-07-16
JP3979662B2 (ja) 2007-09-19
KR970705393A (ko) 1997-10-09
WO1996007413A1 (en) 1996-03-14
ZA957483B (en) 1997-06-06
PL318971A1 (en) 1997-07-21
AP9700939A0 (en) 1997-04-30
ATE267015T1 (de) 2004-06-15
CA2199117A1 (en) 1996-03-14
SK284564B6 (sk) 2005-06-02
NO971015L (no) 1997-03-05
CZ297873B6 (cs) 2007-04-18
BG101284A (en) 1998-03-31
NO313268B1 (no) 2002-09-09
CN1448142A (zh) 2003-10-15
KR100374477B1 (ko) 2003-06-19
SK28197A3 (en) 1997-09-10
CN1111409C (zh) 2003-06-18
JPH10506385A (ja) 1998-06-23
DE69533066D1 (de) 2004-06-24
FI970918A0 (fi) 1997-03-04
AU704977B2 (en) 1999-05-13
US7262213B2 (en) 2007-08-28
CN1251680C (zh) 2006-04-19
EP0781136A1 (en) 1997-07-02
CN1160351A (zh) 1997-09-24
PL189288B1 (pl) 2005-07-29
DK0781136T3 (da) 2004-08-02
US6063787A (en) 2000-05-16
BR9508886A (pt) 1997-12-30
OA10473A (en) 2002-04-08
NZ335013A (en) 2000-07-28
US20050261320A1 (en) 2005-11-24
AU3586295A (en) 1996-03-27
US8076347B2 (en) 2011-12-13
US20080171758A1 (en) 2008-07-17
IL115156A0 (en) 1995-12-31
ES2219666T3 (es) 2004-12-01
HUT77172A (hu) 1998-03-02
CZ63397A3 (en) 1997-07-16
PT781136E (pt) 2004-09-30
IS4434A (is) 1997-03-04
FI970918A (fi) 1997-05-02
NO971015D0 (no) 1997-03-05
DE69533066T2 (de) 2005-06-02
EP0781136B1 (en) 2004-05-19
MY121548A (en) 2006-02-28
RO118748B1 (ro) 2003-10-30
CN1827108A (zh) 2006-09-06
PL188359B1 (pl) 2005-01-31
RU2168995C2 (ru) 2001-06-20
IS2011B (is) 2005-05-13
EP1468687A1 (en) 2004-10-20
SI0781136T1 (en) 2004-08-31
BG63122B1 (en) 2001-04-30
CA2199117C (en) 2006-04-11
EP0781136A4 (en) 1999-06-23

Similar Documents

Publication Publication Date Title
AP783A (en) Composition of L-oddC Compound derivatives and methods of use as antineoplastic agents.
US5817667A (en) Compounds and methods for the treatment of cancer
BG63121B1 (bg) Таксоиди, тяхното получаване и фармацевтични състави, които ги съдържат
US8399420B2 (en) Azacytidine analogues and uses thereof
WO1991019713A1 (en) Pyrimidine nucleoside derivative
US6436948B1 (en) Method for the treatment of psoriasis and genital warts
EP0323441B1 (en) 5-Fluorouracil derivatives
RU2347786C2 (ru) Производные сложноэфирных липидов нуклеотидов
JP5185823B2 (ja) がん治療用ジオキソラン誘導体
NO854692L (no) Fremgangsmaate ved fremstilling av imidazopyridazinderivater.